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Role of adenosine on glucagon-indaced cAMP in a human cortical
collecting duct cell line. The hormonal responsiveness profile of the
cortical collecting duct varies from one species to another. To identify the
hormones and agonists that modulate the functions of this tubule segment
in the human species, we generated a cell line (HCD) immortalized by
SV4O virus. The tubular origin of this cell line was assessed by the
expression of collecting duct-specific antigens and the ability of vasopres-
sin to increase by nine-fold cAMP synthesis. Glucagon and adenosine
stimulated cAMP synthesis, and atrial natriuretic peptide stimulated
cGMP synthesis in a concentration-dependent manner. Bradykinin, aden-
osine and angiotensin increased intracellular calcium concentration
([Ca2]). Because adenosine can regulate tubular functions, we examined
its role on glucagon-induced cAMP synthesis. Using adenosine analogs,
we demonstrated that HCT cells both expressed adenosine type-2 (A2)
receptors which stimulated cAMP production, and adenosine type-I (Al)
receptors linked to [Ca2] increase which inhibited glucagon-stimulated
cAMP synthesis. The inhibitory effect was abolished by pertussis toxin, and
was neither due to [Ca2] increase nor to protein kinase C activation,
which indicated that some Al adenosine receptors were directly negatively
coupled to adenylyl cyclase. These results suggest that adenosine can
modify human cortical collecting duct functions in opposite ways accord.
ing to the adenosine receptor activated.
Our knowledge of human kidney physiology is principally based
on experiments performed on animals or on material obtained
from animals. Some characteristics of the nephron, however, like
hormonal responsiveness, vary from one species to another [1, 2]
making it difficult to extrapolate data obtained in rats, rabbits or
mice to the human species. In human, direct data can be provided
by clearance studies, but they measure only overall effects that
usually cannot be localized with certainty to a specific nephron
segment. Some authors have been successful in microdissecting
and even microperfusing various portions of the human nephron
[3—6]. For obvious reasons these techniques cannot be used on a
large scale, and the data so provided are limited. A way to obtain
a continuous source of material from human kidney is to immor-
talize renal cells of defined origin. We report the establishment
and the characterization of the first human renal cell line derived
from the cortical collecting duct. This tubule portion is known to
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reabsorb water and sodium under the control of AVP, and to
regulate proton and bicarbonate excretion. However, there are
no data available concerning the effects of other hormones on this
segment in the human species. The aim of this study was to
identify the substances that could modify intracellular cAMP or
[Ca2J, and hence regulate human cortical collecting duct func-
tions. Our results indicate that similar to the rat, but contrary to
the rabbit, glucagon stimulates cAMP synthesis in the human
cortical collecting duct. Because production and release of aden-
osine are increased in various conditions [7—10] and adenosine has
been demonstrated to modulate water reabsorbtion in the rabbit
cortical collecting duct [11], we have also considered the role of
adenosine and adenosine analogs on basal and glucagon-induced
cAMP synthesis. This study provides evidence for the presence of
both Al and A2 adenosine receptors in the human cortical
collecting duct. Al receptor activation stimulates a rise of [Ca2]1
and inhibits glucagon-stimulated cAMP production through an
inhibitory guanine nucleotide-binding protein independently of
phospholipase C or protein kinase C activation. A2 receptors
increase cAMP synthesis. These results suggest a dual role of
adenosine in the control of human cortical collecting duct func-
tions.
Methods
Establishment and culture of the cell line
The human collecting duct (HCD) cell line was established
from a kidney that had been removed for a localized adenocarci-
noma. The patient did not present any electrolytic disorder nor
suffered from non-tumoral kidney disease. The non-tumorous
part of the kidney cortex was rapidly dissected under sterile
conditions after nephrectomy and incubated with collagenase. A
tubular cell suspension was then prepared by mechanical dissoci-
ation and sequential sieving according to a method previously
described [12]. The isolated cells were seeded in 25 cm2 Falcon
flasks and cultured at 37°C in a hormonally defined medium [DM:
DMEM-HAM's F12 1:l(vol/vol); transferrin, 5 .tgIm1; sodium
selenate, 50 nM; glutamine, 2 mM; dexamethasone, 5Xl08 M;
insulin, 5 tgIml; Hepes, 20 mt, pH 7.4] containing 2% of new-
born calf serum (NCS) until transfection.
DNA transfection was carried out using the calcium phosphate
co-precipitation method described by Wigler et al [13]. Semi-
confluent primary cultures of renal cells were transfected with 0.5
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mi/flask of DNA-calcium phosphate co-precipitate containing 20
tg of carrier calf thymus DNA plus 2.5 jrg of pSVHB1 recombi-
nant plasmid DNA harboring a complete but replication-defective
SV40 genome [14]. After six hours at 37°C, the medium was
removed, and 5 ml of fresh DM were added per flask. The cultures
were refed with fresh medium every three or four days. Trans-
formed foci appeared after three to four weeks, at which time the
cells were trypsinized and regularly subcultured once a week, with
one or two medium changes between each subculture. The
expression of SV4O-specific large T-antigen in transformed cells
was assessed, at different cell passage levels, by indirect immuno-
fluorescence [15], with syrian hamster anti-S V40 tumor serum and
fluorescein isothiocyanate-conjugated rabbit antiserum to ham-
ster y-globulin. The transformed cell population was then regu-
larly cultured at 37°C in DM containing 2% NCS. This initial
population was cloned twice. Cells were carefully trypsinized to
obtain single cell suspension and seeded at a density of io cells in
100 mm Petri dishes (Falcon Labware, Lincoln Park, NJ, USA).
After few days of culture, single colonies were isolated by
trypsinization in a plastic ring sealed around each specific colony
by means of silicon grease [16]. Several clones were obtained. For
these experiments, we selected a clone stained by the monoclonal
antibody (niAb) 272 that specifically recognizes collecting duct
principal cells in human and rabbit kidney as previously described
[17]. This clone was subcloned, and all the experiments reported
in this paper were performed on the same subclone cultured in
DM containing 2% NCS from passages 15 to 50.
Immunofluorescence
Confluent cultures of cells grown in 35 mm Petri dishes were
fixed in 100% ethanol for five minutes and processed for indirect
immunofluorescence as previously described [17]. The tubular
origin of this cell line was assessed using mAb 272 and an
anti-band 3 monoclonal antibody (IVF12; provided by Dr. V.
Schuster).
For double staining indirect immunofluorescence studies (IF),
the first mAb (IVF 12) was incubated with kidney sections and
detected with Texas red labeled anti-mouse 1g. Sections were then
incubated with pure normal mouse serum. The second mAb
(biotinylated mAb 272) was subsequently added in pure normal
mouse serum to avoid reactivity with the tissue-bound anti-mouse
IgG, and further revealed by FITC-labeled streptavidin.
Expression of Tamm-Horsfall protein was evaluated using
various mAbs previously produced in our laboratory [18]. Cyto-
keratin expression was analyzed using a specific mAb (Amersham,
Les Ulis, France).
Determination of CAMP and cGMP production
At confluence, cells grown in 12-well trays were incubated in
DM at 37°C for 15 minutes with the phosphodiesterase inhibitor,
3-isobutyl 1-methyl xanthine (IBMX), at the concentration of 0.1
m (for cAMP synthesis) or 1 m (for cGMP synthesis). The
medium was then discarded and replaced by DM containing
IBMX and the stimulating agent. After a five minute incubation at
37°C, the medium was quickly removed and the stimulation
stopped by adding 1 ml of ice-cold ethanol 95%-formic acid 5%
solution. After 30 minutes at 4°C, the supernatant was recovered,
evaporated, stored at —20°C and resuspended in 50 m sodium
acetate buffer, pH 6.2 for radioimmunoassay (RIA), Some exper-
iments were conducted in the absence of IBMX. Rolipram 201724
(0.1 jiM), a specific type IV phosphodiesterase inhibitor, and
adenosine deaminase (2 U/ml) were also used when adenosine
effects were studied. For cGMP determinations, samples were
acetylated. At least three independent experiments, each carried
out in triplicate, were performed. cAMP and cGMP were ex-
pressed as pmol and fmol formed per 106 cells, respectively. At
least two culture wells were used for determination of cell number
in each experiment.
Intracellular calcium measurement
At confluence, cells cultured in 100 mm Petri dishes were
loaded at 37°C for 10 minutes with 1.5 jiM Fura2 acetoxymethyl-
ester dissolved in DM. After trypsinization (trypsin 0.05%-EDTA
0.02%, 3 mm at 37°C), cells were washed twice with 10 ml of
PBS and the final pellet was resuspended in 6 ml of PBS
containing 1.8 mM Ca. Two milliliters of cell suspension were
transferred in a quartz cuvette at 37°C under constant stirring and
fluorescence measurements were monitored in a F2000 Hitachi
spectrofluorimeter at 340, 370 nm (excitation wavelengths) and
540 nm (emission wavelength). Maximal fluorescence was ob-
tained with 50 jiM digitonin and minimal fluorescence with 10 mtvi
EGTA. [Ca2I1 was calculated using the formula described by
Grynkiewicz, Poenie and Tsien [191 with a Kd of 224 nM. The
values of [Ca2] given in the text were measured at the peak of
[Ca2I increase.
Material
1-34 Bovine PTH and pertussis toxin were purchased from
Calbiochem (Meudon, France). Salmon calcitonin was from Ciba-
Geigy (Rueil-Malmaison, France). AVP, forskolin, adenosine, 5'
(N6-ethylcarboxamido) adenosine, N6-cyclopentyladenosine, iso-
proterenol and 3-isobutyl-1-methyl-xanthine (IBMX) were from
Sigma Chemical Co. (St. Louis, MO, USA). Glucagon was provided
by Novo Industrie Pharmaceutique (Paris, France). Bisindolylmale-
imide GF 109203X was obtained from Boerhinger Mannheim (Ger-
many). Rat 1-28 atrial natriuretic peptide (ANP) was purchased from
Peninsula laboratories (Belmont, CA, USA).
Statistical analysis
Results are expressed as the mean SEM of at least three
independent experiments performed in triplicate. Statistical anal-
ysis were carried out using ANOVA and Dunnett's t test where
appropriate. A P value of 0.05 was considered statistically signif-
icant.
Results
Origin of the HCD cell line
The HCD cells were stained by a monoclonal antibody pro-
duced in our laboratory, mAb 272, specific for the rabbit collecting
duct principal cells. Similarly in human kidney cortex (Fig. IA),
only the collecting duct was stained, and the reactivity was
restricted to the basolateral domain of a cell subpopulation (Fig.
1A, A1 and A2). In double staining experiments, most cells
unlabeled by mAb 272 were stained with the anti-band 3 mono-
clonal antibody, IVF12 (Fig. 1B, B1 and B2), whereas a few cells,
probably /3-intercalated cells, remained unlabeled by either anti-
body (Fig. 1, arrowheads). These results confirm that mAb 272 is
a marker of principal cells in the human species. All HCD cells
were labeled by mAb 272 (Fig. 1A inset) as well as by IVF12 (Fig.
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Fig. 1. Antigenic characteristics of HCD cells.
Reactivity of antibodies was studied by indirect
immunofluorescence on acetone-fixed cryostat
human kidney Cortex sections (A, B) and on
ethanol-permeabilized HCD cells grown in
plastic Petri dishes (insets). A and B are
photographs of the same section double stained
with mAb 272 (A), a marker of principal cells
in the rabbit collecting duct t171 and an
antibody to band 3, a marker of the a-type
intercalated cells (IVFI2). Only cortical
collecting duct sections are labeled with either
antibody. Note mutually exclusive staining of
the cells by the two antibodies; a few cells,
probably p-intercalated cells are unlabeled
(arrowheads). Al and A2, Bi and B2 are
magnifications of the collecting duct sections
numbered 1 and 2 in A and B, respectively.
Insets: 100% of HCD cells are stained by mAb
272 (A) and the anti-band 3 antibody (B).
Bars = 20
.sm.
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Basal dDAVP GLU ISO PTH CT ADO FK
Fig. 2. cAMP production in HCD cells in response to various stimulating
agents. The experiments were carried out on confluent cells stimulated for
5 minutes in the presence of phosphodiesterase inhibitor (0.1 mti IBMX).
i0 M Forskolin (FK), 10-6 M dDAVP, 10 M glucagon (GLU) and 10-6
M adenosine (ADO) increased cAMP synthesis above basal value. 10—6 M
isoproterenol (ISO), lO M parathormone (PTH) and 100 ng/ml calcito-
nm (CT) had no significant effect on cAMP content. *p < 0.001 compared
to basal values.
lB inset), thereby suggesting the presence of immortalized hybrid
cells. The presence of the Tamm-Horsfall protein, a marker of
the thick ascending limb of Henle's loop, was not detected by
immunofluorescence (not shown).
Hormonal responsiveness
To identify the substances that modulate cortical collecting duct
functions in human species, we measured cAMP and cGMP
accumulation and [Ca2J1 after stimulation by various effector
agents known to act on the renal tubule in different species. As
shown in Figure 2, 106 M glucagon, 106 M dDAVP (a specific
agonist of V2-type AVP receptor) and 10_6 M adenosine signifi-
cantly increased intracellular cAMP content. dDAVP was the
most potent stimulator whereas glucagon and adenosine had
lesser effects (dDAVP 53.5 4.47; glucacon 26.6 1.61; adeno-
sine 18.3 1.41; basal 5.7 0.38 pmol/5 min/106 cells). 10_6 M
isoproterenol, 100 nglml calcitonin (CT) and iO M 1-34 bovine
parathormone (PTH) failed to significantly stimulate cAMP syn-
thesis. Because the amount of cAMP synthesized in response to
stimulation by 10—6 M dDAVP was twice as high as that induced
by 106 M glucagon, we compared the concentration-response
curves of dDAVP and glucagon (Fig. 3) dDAVP significantly
increased cAMP production from iO M. The threshold of
stimulation for glucagon was iO M. Regardless of hormone
concentrations from 10 10 M to 10 M, glucagon-induced cAMP
synthesis was lower than dDAVP-induced cAMP synthesis.
We also investigated the effects of various hormones known to
interact with AVP in rat and rabbit collecting duct. Bradykinin at
a concentration of iO M induced rapid and transient increase
of [Ca2] (Base 180.1 9.2; BK 548.3 36.3 nM; p < 0.0001;
N = 22). Angiotensin II (Ang II) had a biphasic effect on [Ca2].
From 10b0 to 108 M, Ang II increased [Ca2] in a dose-
dependent manner whereas Ang II concentrations  iO M
failed to enhance [Ca2]1 (Fig. 4). Arginine-vasopressin (AVP)
tested from 10b0 to 10—6 M had no effect on [Ca2j1, indicating
that HCD cells do not express the Vi type of AVP receptor.
Because atrial natriuretic peptide (ANP) has been demonstrated
Log (hormone concentration)
Fig. 3. Concentration-response curves for dDA VP () and glucagon (S).
Stimulations were carried out in the presence of phosphodiesterase
inhibitor (0.1 mtvi IBMX) with increasing doses of dDAVP or glucagon.
The thresholds of stimulation were iO and iO M for dDAVP and
glucagon, respectively. Regardless of hormone concentration, dDAVP
was more potent than glucagon in activating cAMP synthesis. *P < 0.05,
compared to basal values.
En
0 —10 —9 —8 —7 —6
Log (Ang II)
Fig. 4. Effects of increasing concentrations of angiotensin II (Ang II) on[Ca2]. Confluent cells were loaded with fura 2, then stimulated by
various concentrations of Ang II. [Ca2] was recorded and calculated as
described in Methods. The values reported here were those calculated at
the peak of [Ca2] increase. The maximum of stimulation was obtained
with io M Ang II. At higher concentrations Ang II effects on [Ca2]1
decreased rapidly. < 0.01 compared to basal value.
to blunt AVP-induced water flux in rabbit cortical collecting duct
[20], we searched for the expression of biologically active ANP
receptors in HCD cells. ANP stimulated cGMP synthesis in a
concentration-dependent fashion from 10—8 M. No plateau was
reached within the range of concentrations studied (Fig. 5).
Characterization of adenosine receptors
Adenosine antagonizes vasopressin-stimulated water reabsorb-
tion and regulates a chloride channel in the rabbit cortical
collecting duct [11, 21], and Al and A2 adencisine receptors are
both expressed in rabbit cortical collecting duct cells [22, 23]. It is
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Log (ANP)
Fig. 5. Effect of ANP on cGMP production. Confluent cells were stimu-
lated for 5 minutes by increasing concentrations of ANP in the presence
of 1 mM IBMX. ANP strongly stimulated cGMP production in a concen-
tration-dependent manner from l0 M. No plateau was reached within
the range of concentrations studied. P < 0.01; statistics were performed
on the Log of results as described in Methods.
60
Log (agonist)
Fig. 6. Comparison of adenosine analog effects on cAMP production. HCT
cells were incubated with increasing concentrations of N6-cyclopentyl-
adenosine (CPA) or 5'(N-ethylcarboxamido)adenoSine (S, NECA).
NECA, an A2 receptor agonist, stimulated cAMP synthesis from iO M
whereas the threshold of stimulation was lO M for CPA, an Al receptor
agonist. < 0.05 compared to basal values.
still unknown, however, whether these two receptors are present
in human collecting duct. To characterize the types of adenosine
receptors expressed in HCD cells, we used two analogs that
exhibit different affinities for adenosine subtypes [24]. We first
compared the effects on cAMP accumulation of 5' (N6-ethylcar-
boxamido) adenosine (NECA), an A2-receptor agonist [24], to
those of N6-cyclopentyladenosine, an Al -receptor agonist [24].
As shown in Figure 6, NECA was a much more potent stimulator
Log (agonist)
Fig. 7. Comparison of adenosine analog effects on [Ca2J,. Cells loaded
with fura 2 were stimulated by CPA or NECA. CPA increased [Ca2j1 in
a concentration-dependent manner from 10 M, the lowest concentration
tested. The maximum of stimulation was observed at 10 M. By compar-
ison the effect of NECA was tested at l0- and 10' M (bars). At both
concentrations, the CPA-induced [Ca2]1 increase was significantly higher
than NECA-elicited [Ca2}1 increase. p < 0.01 compared to basal
concentrations. #P < 0.001 NECA compared to CPA.
*
of cAMP synthesis than CPA. The threshold of stimulation of
adenylate cyclase by NECA was i0 M. In contrast, CPA
significantly increased cAMP content only from iO— M. No
plateau was reached within the range of concentrations studied.
These results suggest that adenosine-stimulated cAMP produc-
tion was essentially linked to A2 receptors. In the experiments
described above, substitution of Rolipram 201724 for IBMX or
preincubation with adenosine deaminase did not significantly
modify the results obtained in the presence of IBMX alone.
To determine if Al adenosine receptors were expressed in
HCD cells, we investigated the effects of NECA and CPA on
[Ca2]. CPA induced a rapid and transient increase of [Ca2]1 in
a dose-dependent manner from i0° M (Fig. 7). Maximal stimu-
lation of [Ca2J was achieved at 106 M CPA (basal 140 2.5 nM;
CPA 10—6 M 581 29.4 nM; P < 0.001). NECA significantly
increased [Ca2] only from 10 M, and the rise of [Ca2]1 was
modest by comparison with CPA (NECA 106 M 271.1 11.8 nM,
P < 0.001 compared to CPA 10_n M), indicating that the adenosine-
elicited increase of [Ca2]1 is coupled to Al receptor activation.
Effect of adenosine on the response to glucagon
Adenosine has been reported to inhibit AVP-stimulated cAMP
production through Al receptor in rabbit and rat collecting duct
[22, 25], but it is unknown if this effect is specific of AVP. We
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Fig. 8. Inhibition of glucagon-induced CAMP production by CPA and
adenosine. HCD cells were stimulated with 10—6 M glucagon alone or
together with adenosine (ADO), NECA, or increasing doses of CPA. CPA
significantly decreased cAMP production in a concentration-dependent
manner from 108 M to 10 M. This inhibition was reproduced by
adenosine but not by NECA. kp < 0.05, 6P < 0.01 compared to glucagon
alone.
therefore examined the effects of io— M adenosine and increasing
concentrations of CPA on intracellular cAMP content when HCD
cells were stimulated by 106 M glucagon (Fig. 8). CPA markedly
inhibited in a concentration-dependent manner glucagon-induced
cAMP accumulation: the threshold of inhibition was 108 M and
__________
the maximum was reached at 106 M CPA (77.3% inhibition).
This inhibition was reproduced by iO M adenosine but not by
iO M NECA (Fig. 8). These results indicate that adenosine
inhibits glucagon-induced cAMP by stimulating Al receptors.
Mechanism of the inhibition of glucagon-elicited cAMP production
To further analyze the interactions between glucagon and CPA,
HCD cells were preincubated for 18 hours in the presence of
1 .tg/ml pertussis toxin (PT) prior to incubation with 10 M CPA
and l0_6 M glucagon. Under these conditions, PT completely
__________
reversed CPA-induced inhibition on glucagon-stimulated cAMP
production (Fig. 9). PT also abolished the rise of [Ca2I1 in
response to CPA (data not shown), thus making it difficult to
determine whether inhibition of glucagon response was linked to
[Ca2J increase and/or phospholipase C activation or solely due
to stimulation of a Gi protein coupled to adenylyl cyclase. To
address this issue, HCD cells were stimulated by l0 M glucagon
alone or together with 10 M ionomycine, a calcium ionophore.
lonomycine did not alter glucagon-induced cAMP production
(glucagon 18.1 2.6; glucagon + ionomycine 17.9 1.7 pmol
cAMP/5 min/106 cells) demonstrating that [Ca2] increase by
itself did not account for the inhibitory effect of adenosine. To
determine if the inhibition was due to protein kinase C (PKC)
activation, HCD cells were incubated for 30 minutes with l0_6 M
of Bisindolylmaleimide GF 109203X, a potent and highly selective
PKC inhibitor [261. We compared the inhibitory effect of CPA on
glucagon-induced cAMP synthesis in untreated and Bisindolyl-
maleimide-treated cells. As shown in Figure 10, the inhibition of
PKC did not reverse the CPA inhibition. Similar results were
obtained with 10_b M calphostin, another PKC inhibitor (data not
30
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Fig. 9. Effect of pertussis toxin (PT) pretreatment on CPA-induced inhibi-
tion of the CAMP response to glucagon. HCT cells were preincubated for
18 hours with either 1 tWml of PT or usual medium, then stimulated by
10_6 M glucagon alone or together with 10_6 M CPA. PT pretreatment
completely reversed CPA-induced inhibition of glucagon-stimulated
cAMP synthesis. < 0.01 compared to glucagon alone.
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GLU
Fig. 10. Effect of protein kinase C inhibition on the inhibito,y effect of CPA.
Cells were incubated either with 10—6 M glucagon alone or together with
106 M CPA. cAMP production was compared in control cells and in cells
pretreated for 30 minutes with io M Bisindolylmaleimide OF 109203X
(GF). CPA significantly inhibited the cAMP response to glucagon. Inhi-
bition of PKC by GF could not reverse this effect. < 0.01 compared to
glucagon alone.
shown). These results thus indicate that the inhibition of gluca-
gon-stimulated cAMP by adenosine was not due to PKC activa-
tion, and therefore suggest a direct negative coupling of adenosine
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Al receptor with adenylyl cyclase through a pertussis toxin-
sensitive Gi protein.
Discussion
We report the characteristics of the first human renal cell line
deriving from the cortical collecting duct. The tubular origin of
HCD cells is supported by immunomorphological studies and
hormonal responsiveness profile. First, HCD cells are labeled by
mAb 272, a monoclonal antibody that specifically binds to the
basolateral domain of principal cells in human and rabbit kidney
(Fig. 1). Second, AVP strongly stimulates cAMP production in
HCD cells. The single site of action of AVP in terms of cAMP
synthesis in the human kidney is the collecting duct [5, 61 and it is
admitted that the main target of AVP in the collecting duct is the
principal cell which regulates water reabsorption. We therefore
conclude that HCD cells derive from the collecting duct and
express principal cell characteristics. This cell line also expresses
band-3 antigen, a feature usually attributed to a-type intercalated
cells but contrary to intercalated cells, does not respond to
isoproterenol. The coexistence of principal cell and intercalated
cell properties in HCD cells is not due to the heterogeneity of the
cell population because the HCD cell line has been cloned twice.
Furthermore the principal- and intercalated-cell antigens are both
expressed in 100% of the cells. Such a colocalization of principal-
and intercalated-cell antigens in the same cells has already been
reported. The first evidence that some cells can share principal
cell and intercalated cell properties was provided by Hagège,
Gabe and Richet 20 years ago who described intermediary cell
forms in animals with various diets [27]. This observation was
recently confirmed by Fejes-Tóth and Náray-Fejes-Tóth who
demonstrated the existence of principal/intercalated hybrid cells
in the rabbit collecting duct in situ, in primary cultures of
collecting tubule cells and in a mouse collecting duct cell line [28].
We have also reported the expression of intercalated cell markers
in a clonal rabbit cortical collecting duct cell line exhibiting
antigenic and functional characteristics of principal cells [17].
The second aim of this study was to identify the various agents
and hormones that potentially modulate cortical collecting duct
functions in the human. Glucagon stimulates cAMP synthesis in
the cortical and outer medullary segments of the rat collecting
duct [29, 30] and increases urine osmolality, free water reabsorp-
tion and fractional excretion of urea [31, 32]. Contrary to the rat
collecting duct, the rabbit collecting duct is insensitive to glucagon
[1, 2]. In human kidney, glucagon increases cAMP synthesis in
renal medulla homogenates, but it is difficult under these exper-
imental conditions to determine the precise site of action of
glucagon [33]. No data regarding the effects of glucagon on human
renal cortex or on the collecting duct are available. HCD cells
express glucagon receptors coupled to adenylyl cyclase indicating
that glucagon can modulate human collecting duct functions. To
our knowledge, this is the first evidence of the presence of
glucagon receptors in human cortical collecting duct. ANP inhib-
its AVP-stimulated water flux in rat and rabbit cortical collecting
duct at a post-cAMP synthesis step by increasing cGMP [20, 34].
In the human kidney, ANP receptors have been characterized in
the glomerulus [35, 36]. We report here that ANP receptors
coupled to cGMP synthesis are also present in human cortical
collecting duct cells, indicating that ANP actions are not restricted
to the glomerulus in the human kidney. Angiotensin receptors
have been detected in the kidney of various species and localized
to the glomerulus, the proximal tubule, and the thick ascending
limb. To our knowledge, they have not yet been described in the
collecting duct. The angiotensin receptors expressed in HCD cells
increase [Ca2] suggesting that they are type-i angiotensin
receptors.
We focused on the effects of adenosine and its analogs on HCD
cells. Ischemia, anemia or saline loading induce adenosine release
by the kidney [7—101. Adenosine is not only a vasoactive com-
pound, it also has direct effects on glomeruli and tubules [11, 37].
Adenosine effects are mediated by two types of receptors: type-I
(Al) adenosine receptors are generally linked to phospholipase C
activation or negatively coupled to adenylyl cyclase activation
through a pertussis toxin-sensitive protein G; they exhibit high
affinity for CPA [24, 31• Type-2 (A2) adenosine receptors stim-
ulate adenylyl cyclase and are preferentially activated by NECA
[24, 371. Both types have been described in the kidney, in the
glomerulus [381, the thick ascending limb [39, 40] and cultures or
cell lines derived from the cortical and inner medullaiy segments
of the collecting duct [22, 23, 25]. In cultures of rabbit collecting
duct cells, adenosine and Al adenosine receptor agonists inhibit
AVP-induced cAMP formation, whereas A2 receptor agonists
stimulate cAMP formation [22, 23]. In human kidney, adenosine
stimulates cAMP synthesis in the papilla [41]. A selective adeno-
sine Al receptor antagonist given to healthy human subjects
modified the excretion of various ions, particularly sodium, potas-
sium and bicarbonate, suggesting a tubular localization of aden-
osine receptors [421. In the I-lCD cell line, the two types of
receptors are present, linked to different transduction pathways.
Adenosine A2 receptors stimulated cAMP synthesis and had no
effect on response to glucagon. On the other hand, activation of
adenosine Al receptors induced [Ca2j1 increase and inhibited
glucagon-stimulated cAMP formation. This inhibitory effect was
abolished by pertussis toxin pretreatment and was neither due to
[Ca2]1 increase nor to protein kinase C activation, which suggests
that a subpopulation of adenosine Al receptors is directly nega-
tively coupled to adenylyl cyclase via a Gi protein.
The presence of the two types of adenosine receptors in a single
cell deserves further discussion. First, it might be argued that one
or both types of adenosine receptors were induced by the process
of culturing or transforming the cells. Such a possibility seems
unlikely because both functional and gene expression studies
support the presence of Al [43,44] and A2 [11] receptors in the
collecting duct in viva. Second, since HCD cells also express band
3, one cannot exclude that Al and A2 receptors are expressed in
viva on different cell types, that is, on intercalated and principal
cells. However, in perfused collecting ducts, A2 receptor stimula-
tion increases [11] whereas Al receptor stimulation decreases [43]
hydraulic conductivity, a property specific of principal cells.
Coexpression of Al and A2 adenosine receptors on the same cell
has already been reported for rabbit cortical collecting duct cells
[23], rat inner medullary collecting duct cells [25], and LLC-PK1
cells [45]. Third, the dual expression of adenosine receptors with
differential effects on cAMP production in principal cells of the
human cortical collecting duct may be of physiological impor-
tance, because it suggests that depending on its extracellular
concentration, adenosine can exert opposite effects on tubule
functions. The affinity of Al receptors for adenosine is in the
nanomolar range. Adenosine A2 receptors exhibit a lower affinity
within the micromolar range [36]. Adenosine synthesis is regu-
lated by the activity of the ecto-5'-nucleotidase that can be
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modulated in various physiological or pathological situations, in
particular hypoxia or anemia l0]. This enzyme is expressed in
intercalated cells in the rat collecting duct [46], suggesting that
adenosine concentration may be locally controlled. Depending on
the level of adenosine concentration reached, adenosine Al or A2
receptors could be stimulated with opposite resulting effects on
cortical collecting duct cell functions.
In conclusion, we have established the first human renal cell
line derived from the cortical collecting duct. This cell line has
retained antigen ic characteristics of principal and intercalated
cells. Its hormonal responsiveness profile suggests that in addition
to AVP, the human cortical collecting duct is responsive to
glucagon, which stimulates cAMP synthesis, and to adenosine,
which can increase or diminish intracellular cAMP content de-
pending on its extracellular concentration. This cell line repre-
sents a unique tool to study the properties of human cortical
collecting duct cells.
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